The costs of treating acute heart failure: an economic analysis of the SURVIVE trial
Authors:
- Gregory de LissovoyGLGregory de Lissovoy
- Kathy FraemanKFKathy Fraeman
- Jeff SalonJSJeff Salon
- Tatia Chay WoodwardTWTatia Chay Woodward
- Raimund SterzRSRaimund Sterz
- 1 January 2008
- journal article
- research article
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 11 (3) , 415-429
Abstract
To estimate the incremental cost per life year gained with levosimendan relative to dobutamine in treatment of acute heart failure based on the Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support (SURVIVE) trial. SURVIVE enrolled 1,327 patients (levosimendan 664, dobutamine 663) from nine nations with 180-day survival from date of randomisation as the primary endpoint. Hospital resource utilisation was determined via clinical case reports. Unit costs were derived from hospital payment schedules for France, Germany and the UK, and represent a third-party payer perspective. Cost-effectiveness analysis was performed for a subset of the SURVIVE patient population selected in accordance with current levosimendan labeling. Mortality in the levosimendan group was 26 versus 28% for dobutamine (hazard ratio 0.91, 95% confidence interval 0.74-1.13, p=0.40). Initial hospitalisation length of stay was identical (levosimendan 14.4, dobutamine 14.5, p=0.98). Slightly lower rates of readmission were observed for levosimendan relative to dobutamine at 31 (p=0.13) and 180 days (p=0.23). Mean costs excluding study drug were equivalent for the index admission (levosimendan euro5,060, dobutamine euro4,952; p=0.91) and complete episode (levosimendan euro5,396, dobutamine euro5,275; p=0.93). At an acquisition cost of euro600 per vial, there is at least 50% likelihood that levosimendan is cost effective relative to dobutamine if willingness to pay is equal to or greater than euro15,000 per life year gained.Keywords
This publication has 19 references indexed in Scilit:
- Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart FailureJAMA, 2007
- Review of Current and Investigational Pharmacologic Agents for Acute Heart Failure SyndromesThe American Journal of Cardiology, 2007
- Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized With Acute Heart FailureJAMA, 2006
- The association between blood pressure and mortality in patients with heart failureAmerican Heart Journal, 2006
- Reassessment of Dobutamine, Dopamine, and Milrinone in the Management of Acute Heart Failure SyndromesThe American Journal of Cardiology, 2005
- Risk Stratification for In-Hospital Mortality in Acutely Decompensated Heart FailureClassification and Regression Tree AnalysisJAMA, 2005
- Risk stratification after hospitalization for decompensated heart failureJournal of Cardiac Failure, 2004
- A multivariate model for predicting mortality in patients with heart failure and systolic dysfunctionThe American Journal of Medicine, 2004
- The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosisEuropean Heart Journal, 2003
- Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical AccuracyStatistical Science, 1986